

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

SENATE BILL 159

50TH LEGISLATURE - STATE OF NEW MEXICO - SECOND SESSION, 2012

INTRODUCED BY

Bernadette M. Sanchez

AN ACT

RELATING TO HEALTH CARE; MANDATING PROCEDURES RELATING TO THE
PRESCRIBING AND DISPENSING OF CERTAIN PRESCRIPTIONS FOR OPIOID
MEDICATIONS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

SECTION 1. A new section of the New Mexico Drug, Device
and Cosmetic Act is enacted to read:

"~~[NEW MATERIAL]~~ OPIOID MEDICATION--CONSENT REQUIRED--
PATIENT EDUCATION--SUPPLY LIMITS--LABELING--PROTOCOLS FOR
DISPENSING CERTAIN PRESCRIBED OPIOID MEDICATIONS.--

A. Before initiating therapy with an opioid
medication to a patient that resides in the state, a
practitioner shall obtain written consent from:

(1) the patient for whom the practitioner
wishes to prescribe the opioid medication, if the patient is an

underscoring material = new
~~[bracketed material] = delete~~

1 adult;

2 (2) the patient's parent, guardian or legal
3 representative, if the patient is a minor;

4 (3) the patient's guardian or legal
5 representative, if the patient is an adult who has been judged
6 to be incompetent to provide informed consent; or

7 (4) the patient's surrogate appointed pursuant
8 to Section 24-7A-5 NMSA 1978.

9 B. Before issuing a prescription for an opioid
10 medication, a practitioner shall discuss with the patient or
11 the patient's parent, legal guardian or legal representative
12 the risks and benefits of using opioid medication and shall
13 provide the patient or the patient's parent, legal guardian or
14 legal representative with written materials containing current,
15 factual information on the risks associated with using opioids
16 and on the safe use of opioids.

17 C. Notwithstanding any other provision of law,
18 consent and counseling are not required pursuant to Subsections
19 A and B of this section when health care decisions are made
20 pursuant to the provisions of Chapter 24, Article 10 NMSA 1978.

21 D. A prescription for an opioid medication shall
22 not be refilled.

23 E. For an opioid medication prescription issued by
24 a practitioner licensed under the Dental Health Care Act,
25 excluding an opioid medication prescription issued for oral or

.188028.7

underscoring material = new
~~[bracketed material] = delete~~

1 maxillofacial surgery, a prescriber shall not prescribe and a
2 dispenser shall not fill the prescription in an amount that
3 exceeds a three-day supply. A practitioner issuing an opioid
4 medication prescription for oral or maxillofacial surgery shall
5 adhere to the opioid medication prescribing limits set forth in
6 Subsection F of this section.

7 F. For an opioid medication prescription issued by
8 a practitioner, including a prescription for oral or
9 maxillofacial surgery and otherwise excluding a practitioner
10 licensed under the Dental Health Care Act, a prescriber shall
11 indicate dosage instructions on the prescription. A prescriber
12 shall not prescribe and a dispenser shall not fill the
13 prescription in an amount that exceeds the limits set forth in
14 this subsection:

15 (1) a thirty-day supply, where the patient has
16 been diagnosed with cancer pain, chronic pain or is a hospice
17 patient, except in the following circumstance, which relates
18 only to opioid medications that are Schedule II controlled
19 substances that are prescribed by an individual practitioner:

20 (a) the practitioner may issue multiple
21 prescriptions for the same opioid medication at one time;

22 (b) no single prescription may exceed a
23 thirty-day supply;

24 (c) the total days of medication from
25 multiple prescriptions issued at one time shall not exceed

.188028.7

1 ninety days; and

2 (d) the prescriptions may only be filled
3 one at a time, with no less than a twenty-one-day interval
4 between fills for the same opioid medication;

5 (2) a seven-day supply, where the patient has
6 been diagnosed with acute pain or cough, except as provided in
7 Paragraph (3) of this subsection; and

8 (3) a thirty-day supply, where the patient has
9 not been diagnosed with cancer pain or chronic pain and:

10 (a) twenty-eight days have passed after
11 the prescriber has issued an initial prescription for opioid
12 medication to treat a specified indication or indications; and

13 (b) the prescriber reasonably believes
14 that the patient's pain situation will become chronic. In this
15 case, the prescriber shall specify the underlying diagnosis
16 believed to be the cause of the pain.

17 G. A practitioner when issuing a prescription for
18 an opioid medication shall include in the prescription whether
19 the indication for which it has been prescribed is for acute
20 pain, chronic pain, cancer pain, cough, diarrhea, opioid
21 replacement therapy or hospice care. When the indication is
22 chronic pain, the underlying diagnosis believed to be the cause
23 of the chronic pain shall be specified.

24 H. A dispenser of an opioid medication shall
25 include the indication for which the opioid medication was

underscoring material = new
~~[bracketed material] = delete~~

1 prescribed with the medication's directions for use on the
2 dispensing container label as required pursuant to Subsection B
3 of Section 26-1-16 NMSA 1978. The indication shall state
4 whether the opioid medication has been prescribed for acute
5 pain, chronic pain, cancer pain, cough, diarrhea, opioid
6 replacement therapy or hospice care. When the indication is
7 chronic pain, the underlying diagnosis believed to be the cause
8 of the chronic pain shall be specified.

9 I. When a patient who is a minor seeks to fill a
10 prescription for an opioid medication by presenting the
11 prescription to a dispenser, or when that patient seeks to
12 obtain a filled opioid medication prescription from a
13 dispenser, the minor patient shall be accompanied by the
14 patient's parent, guardian or legal representative.

15 J. A practitioner shall retain a copy of the
16 written consent obtained pursuant to Subsection A of this
17 section for a period of time that the board shall designate by
18 rule.

19 K. A practitioner who treats a patient with an
20 opioid medication for at least one month shall review a board
21 of pharmacy prescription drug monitoring report for that
22 patient as defined by the provider's licensing board. The
23 practitioner's licensing board operating pursuant to Chapter 61
24 NMSA 1978 shall enforce the provisions of this subsection.

25 L. For the purposes of this section:

.188028.7

1 (1) "adequate directions for use" means
2 directions pursuant to which a layperson can use a drug or
3 device safely and for the purposes for which it is intended;

4 (2) "adult" means an individual who is:

5 (a) over eighteen years of age; or

6 (b) under eighteen and emancipated;

7 (3) "dispenser" means a person who delivers an
8 opioid medication to the opioid medication's ultimate user, but
9 "dispenser" does not mean:

10 (a) a licensed hospital pharmacy that
11 distributes opioid medications for the purpose of inpatient
12 hospital care;

13 (b) a practitioner or other authorized
14 person who directly administers an opioid medication to a
15 patient;

16 (c) a wholesale distributor of a
17 Schedule II, III, IV or V controlled substance; or

18 (d) a health facility that the
19 department of health licenses as a clinic, urgent care or
20 emergency facility that dispenses no more than four dosage
21 units to an individual patient within a twenty-four-hour
22 period;

23 (4) "emancipated" means the status of being
24 between sixteen years of age and eighteen years of age and:

25 (a) married;

1 (b) on active duty in the armed forces;

2 or

3 (c) having been declared by court order
4 to be emancipated;

5 (5) "minor" means an individual under the age
6 of eighteen who is not emancipated;

7 (6) "opioid medication" means a substance
8 that:

9 (a) binds to and stimulates the opioid
10 receptors on the surface of the cell;

11 (b) is specifically indicated to treat
12 acute pain, chronic pain or cancer pain, cough suppression or
13 diarrhea, or for opioid replacement therapy or hospice care;

14 (c) is a dangerous drug; and

15 (d) is a Schedule II, III, IV or V
16 controlled substance included in the Controlled Substances Act;
17 and

18 (7) "Schedule II controlled substance" means a
19 controlled substance listed in Schedule II of the Controlled
20 Substances Act."